Eli Lilly and (LLY) 10-Q 27 Oct 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 23, 2017
Document & Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	Lilly Eli & Co
Entity Central Index Key	59,478
Current Fiscal Year End Date	--12-31
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,101,094,711

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue	$ 5,658	$ 5,191.7	$ 16,710.6	$ 15,461.6
Costs, expenses, and other:
Cost of sales	1,566.1	1,400.9	4,445.4	4,188.9
Research and development	1,319.4	1,236.4	3,808.6	3,793.3
Marketing, selling, and administrative	1,555.5	1,565.4	4,807.6	4,661.9
Acquired in-process research and development (Note 3)	205	0	1,062.6	0
Asset impairment, restructuring, and other special charges (Note 5)	406.5	45.5	670.4	234.9
Other–net, (income) expense (Note 12)	13.9	(27.2)	2.7	100.6
Cost of sales, operating expenses, and other-net	5,066.4	4,221	14,797.3	12,979.6
Income before income taxes	591.6	970.7	1,913.3	2,482
Income taxes (Note 8)	36	192.7	460.5	516.2
Net income	$ 555.6	$ 778	$ 1,452.8	$ 1,965.8
Earnings per share:
Basic (usd per share)	$ 0.53	$ 0.74	$ 1.38	$ 1.86
Diluted (usd per share)	$ 0.53	$ 0.73	$ 1.37	$ 1.85
Shares used in calculation of earnings per share:
Basic (shares)	1,053.4	1,057.7	1,054.8	1,058.4
Diluted (shares)	1,056	1,060.8	1,057	1,061.1
Dividends paid per share (usd per share)	$ 0.52	$ 0.51	$ 1.56	$ 1.53

Consolidated Condensed Stateme3

Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income		$ 555.6	$ 778	$ 1,452.8	$ 1,965.8
Other comprehensive income, net of tax (Note 11)	[1]	167.7	113.5	651.2	323
Comprehensive income		$ 723.3	$ 891.5	$ 2,104	$ 2,288.8
[1]	Other comprehensive income (loss) for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million of other comprehensive income attributable to controlling interest, respectively, and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to non-controlling interest, respectively. Other comprehensive income (loss) for the three and nine months ended September 30, 2016 attributable to non-controlling interest is immaterial.

Consolidated Condensed Stateme4

Consolidated Condensed Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Comprehensive income, parent portion	$ 165.5	$ 664.6
Comprehensive income, noncontrolling interest	$ 2.2	$ (13.4)

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents (Note 6)	$ 3,724.3	$ 4,582.1
Short-term investments (Note 6)	3,218.8	1,456.5
Accounts receivable, net of allowances of $42.1 (2017) and $40.3 (2016)	4,401.3	4,029.4
Other receivables	613.2	736.9
Inventories	4,406.9	3,561.9
Prepaid expenses and other	1,063.9	734.6
Total current assets	17,428.4	15,101.4
Other Assets
Investments (Note 6)	6,148.7	5,207.5
Goodwill	4,365.6	3,972.7
Other intangibles	4,271.6	4,357.9
Sundry	2,197.6	1,913.8
Total other assets	16,983.5	15,451.9
Property and Equipment
Land, buildings, equipment, and construction in progress	17,730.7	16,777.6
Accumulated depreciation	(9,132.2)	(8,525)
Property and equipment, net	8,598.5	8,252.6
Total assets	43,010.4	38,805.9
Current Liabilities
Short-term borrowings and current maturities of long-term debt	3,538.1	1,937.4
Accounts payable	1,200.1	1,349.3
Employee compensation	821.1	896.9
Sales rebates and discounts	4,332.7	3,914.9
Dividends payable	0	548.1
Income taxes payable	414.4	119.1
Other current liabilities	2,360.1	2,220.9
Total current liabilities	12,666.5	10,986.6
Other Liabilities
Long-term debt	9,926.6	8,367.8
Accrued retirement benefits (Note 9)	2,458.1	2,453.9
Long-term income taxes payable	710	688.9
Other noncurrent liabilities	2,288.6	2,228.2
Total other liabilities	15,383.3	13,738.8
Eli Lilly and Company Shareholders’ Equity (Note 7)
Common stock	688.5	688.5
Additional paid-in capital	5,754.7	5,640.6
Retained earnings	16,145.5	16,046.3
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 11)	(4,609.4)	(5,274)
Cost of common stock in treasury	(75.8)	(80.5)
Total Eli Lilly and Company shareholders’ equity	14,890.3	14,007.7
Noncontrolling interests	70.3	72.8
Total equity	14,960.6	14,080.5
Total liabilities and equity	$ 43,010.4	$ 38,805.9

Consolidated Condensed Balance6

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Receivables, Net, Current [Abstract]
Allowance for bad debt	$ 42.1	$ 40.3

Consolidated Condensed Stateme7

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net Cash Provided by Operating Activities [Abstract]
Net income	$ 1,452.8	$ 1,965.8
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,155.4	1,152
Change in deferred income taxes	151.7	350.8
Stock-based compensation expense	209.1	188.5
Acquired in-process research and development	1,062.6	0
Other changes in operating assets and liabilities, net of acquisitions	(525.2)	(1,110.8)
Other non-cash operating activities, net	365.7	298.2
Net Cash Provided by Operating Activities	3,872.1	2,844.5
Cash Flows from Investing Activities
Net purchases of property and equipment	(633.3)	(627.2)
Proceeds from sales and maturities of short-term investments	2,320.2	1,245.9
Purchases of short-term investments	(2,973.8)	(425.7)
Proceeds from sales of noncurrent investments	1,686.9	1,606.8
Purchases of noncurrent investments	(3,739.6)	(3,640.7)
Cash paid for acquisitions, net of cash acquired (Note 3)	(882.1)	(45)
Purchase of in-process research and development (Note 3)	(1,036.8)	0
Other investing activities, net	(178)	(75.1)
Net Cash Used for Investing Activities	(5,436.5)	(1,961)
Cash Flows from Financing Activities
Dividends paid	(1,643.8)	(1,617.4)
Net change in short-term borrowings	1,226.8	(1.7)
Proceeds from issuance of long-term debt	2,232	1,206.6
Repayments of long-term debt	(630.6)	(0.2)
Purchases of common stock	(199.9)	(300.1)
Other financing activities, net	(299.6)	(232.2)
Net Cash Provided by (Used for) Financing Activities	684.9	(945)
Effect of exchange rate changes on cash and cash equivalents	21.7	(115.9)
Net decrease in cash and cash equivalents	(857.8)	(177.4)
Cash and cash equivalents at January 1	4,582.1	3,666.4
Cash and Cash Equivalents at September 30	$ 3,724.3	$ 3,489

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 . We issue our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing. Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. These reclassifications include $110.4 million that increased net cash provided by operating activities and increased net cash used for financing activities on the consolidated condensed statements of cash flows as a result of our adoption in the fourth quarter of 2016 of Accounting Standards Update 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting as discussed in our Annual Report on Form 10-K for the year ended December 31, 2016. All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.

Implementation of New Financial

Implementation of New Financial Accounting Pronouncements	9 Months Ended
	Sep. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Implementation of New Financial Accounting Pronouncements	Implementation of New Financial Accounting Pronouncements The following table provides a brief description of accounting standards that have not yet been adopted and could have a material effect on our financial statements: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers This standard will replace existing revenue recognition standards and will require entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach. This standard is effective January 1, 2018, and we will adopt on that date. We are in the process of completing our evaluation of the impact of adopting the standard. We have identified two revenue streams from our contracts with customers: 1) product sales, which represented 96 percent of our 2016 consolidated revenue and 2) licensing and other arrangements, which represented 4 percent of our 2016 consolidated revenue. We are also evaluating the new disclosures required by the standard to determine what additional information will need to be disclosed. Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities This standard will require entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. This standard is effective January 1, 2018, and we will adopt on that date. We are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption. Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2016-02, Leases This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. This standard requires a modified retrospective approach to adoption. This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on January 1, 2019. We are in the process of determining the impact on our consolidated financial statements. Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory This standard will require entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified This standard is effective January 1, 2018, and we will adopt on that date. We are continuing to assess the potential impact of this standard on our consolidated financial statements and currently estimate that the cumulative effect of initially applying the standard would result in an increase to deferred tax assets and the opening balance of retained earnings of approximately $2 billion on January 1, 2018. This estimate is subject to change based upon intra-entity transfers of assets other than inventory over the remainder of 2017 and ongoing assessments of the future deductibility and realizability of the deferred tax assets that would result from implementation. Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Currently, the costs of the other components along with the service cost component are classified based upon the function of the employee. This standard will require entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost will be presented separately from the line items that include the service cost component. When applicable, the service cost component will be the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. This standard is effective January 1, 2018, and we will adopt this standard on that date. Upon adoption of this standard, pension and postretirement benefit cost components other than service costs will be presented in other–net, (income) expense. We do not expect the application of the new standard to have a material impact on consolidated net income either at initial implementation or on an ongoing basis.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Acquisitions	Acquisitions On January 3, 2017, we completed the acquisition of Boehringer Ingelheim Vetmedica, Inc.'s United States (U.S.) feline, canine, and rabies vaccine portfolio and other related assets (BIVIVP). This transaction, as further discussed in this note below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition are included in our consolidated condensed financial statements from the date of acquisition. In addition to the acquisition of a business, we also acquired assets in development in the nine months ended September 30, 2017 , which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired in-process research and development (IPR&D) charges related to these products were immediately expensed because the products had no alternative future use. There were acquired IPR&D charges of $205.0 million and $1.06 billion for the three and nine months ended September 30, 2017 , respectively. There were no acquired IPR&D charges for the three and nine months ended September 30, 2016 . In October 2017, we entered into a global immuno-oncology collaboration agreement with CureVac AG (CureVac), to develop and commercialize up to five potential cancer vaccine products based on CureVac's proprietary RNActive ® technology. This transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Subject to the closing of this transaction, CureVac will receive from us an initial payment of $50.0 million . CureVac will also be eligible to receive potential development and commercialization milestones, as well as tiered royalty payments based on future sales. We anticipate recording an acquired IPR&D charge of approximately $50 million upon the closing of the transaction. Acquisition of a Business Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition Overview of Transaction We acquired BIVIVP in an all-cash transaction for $882.1 million . Under the terms of the agreement, we acquired a manufacturing and research and development site, a U.S. vaccine portfolio, including vaccines used for the treatment of bordetella, Lyme disease, rabies, and parvovirus, among others. Assets Acquired and Liabilities Assumed Our access to BIVIVP information was limited prior to the acquisition. As a consequence, we are in the process of determining the fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets, inventory, property and equipment, accrued expenses, and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from, and require changes to, the preliminary amounts recognized. The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 3, 2017 Inventories $ 108.6 Marketed products (1) 298.0 Property and equipment 148.2 Other assets and liabilities - net 5.2 Total identifiable net assets 560.0 Goodwill (2) 322.1 Total consideration transferred - net of cash acquired $ 882.1 (1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years . (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. We anticipate that the goodwill associated with this acquisition will be deductible for tax purposes. Our consolidated condensed statement of operations for the three and nine months ended September 30, 2017 , includes BIVIVP revenue of $61.2 million and $180.2 million , respectively. BIVIVP has been integrated into our animal health products segment and, as a result of these integration efforts, certain parts of the animal health business were operating on a combined basis during these periods, and we could not distinguish the operations between BIVIVP and our legacy animal health products business. Asset Acquisitions The following table and narrative summarizes our asset acquisitions during the nine months ended September 30, 2017 . There was no asset acquisition which resulted in acquired IPR&D expense during the nine months ended September 30, 2016 . Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense CoLucid Pharmaceuticals, Inc. (CoLucid) Oral therapy for the acute treatment of migraine - lasmiditan March 2017 Phase III $ 857.6 KeyBioscience AG (KeyBioscience) Multiple molecules for treatment of metabolic disorders July 2017 Phase II $ 55.0 Nektar Therapeutics (Nektar) Immunological therapy - NKTR-358 August 2017 Phase I $ 150.0 (1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. In connection with the arrangements described herein, our partners may be entitled to future royalties and/or commercial milestones based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the compounds through the development process. We acquired lasmiditan by acquiring CoLucid. Under the terms of the agreement, we acquired all shares of CoLucid for a cash purchase price of $831.8 million , net of cash acquired, plus net accrued liabilities assumed of $25.8 million . Substantially all of the value of CoLucid was related to lasmiditan, its only significant asset. The acquired IPR&D expense is not tax deductible. Our collaboration agreement with KeyBioscience provides us with access to KeyBioscience's Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, along with multiple molecules. Prior to entering into the agreement, KeyBioscience had initiated Phase II development of the lead molecule. The other assets included in the collaboration range from pre-clinical to Phase I development. Under the terms of the agreement, we receive worldwide rights to develop and commercialize these molecules. Our collaboration with Nektar is to co-develop Nektar's compound which has the potential to treat a number of autoimmune and other chronic inflammatory conditions. Under the terms of the agreement, we are responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.

Collaborations and Other Arrang

Collaborations and Other Arrangements	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations and Other Arrangements	Collaborations and Other Arrangements We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. Elements within a collaboration are separated into individual units of accounting if they have standalone value from other elements within the arrangement. In these situations, the arrangement consideration is allocated to the elements on a relative selling price basis. Revenue related to products we sell pursuant to these arrangements are included in net product revenue, while other sources of revenue (e.g., royalties and profit-sharing due from our partner) are included in collaboration and other revenue. The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated condensed statements of operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Collaboration and other revenue $ 334.2 $ 216.5 $ 869.1 $ 607.3 Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. Boehringer Ingelheim Diabetes Collaboration We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta ™ , Jentadueto ® , Jardiance ® , Glyxambi ® , and Synjardy ® , as well as our basal insulin: Basaglar ® . The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration: Year Launched Milestones (Deferred) Capitalized (1) Product Family U.S. Europe Japan Year Amount Trajenta (2) 2011 2011 2011 Cumulative (4) - all prior to 2016 $ 446.4 Jardiance (3) 2014 2014 2015 Cumulative (4) - all prior to 2016 299.5 Basaglar 2016 2015 2015 2017 — 2016 (187.5 ) Cumulative (4) (250.0 ) (1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales. (2) Jentadueto is included in the Trajenta family of product results. (3) Glyxambi and Synjardy are included in the Jardiance family of product results. (4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period. In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales. The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Trajenta $ 153.3 $ 115.4 $ 408.2 $ 330.8 Jardiance 127.2 47.5 304.3 125.8 Basaglar 145.7 19.4 278.3 46.6 Erbitux ® We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (collectively, North America) will remain with Merck KGaA (Merck) upon expiration of that agreement. The following table summarizes our revenue recognized with respect to Erbitux: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net product revenue $ 137.6 $ 155.9 $ 403.3 $ 455.8 Collaboration and other revenue 25.9 28.7 73.7 77.5 Revenue $ 163.5 $ 184.6 $ 477.0 $ 533.3 Bristol-Myers Squibb Company Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provide consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability. See Note 6 for discussion regarding the estimation of this liability. Merck KGaA A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights. Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. Effient ® We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories. Territory Marketing Rights Selling Party U.S. Co-promotion Lilly Major European markets Co-promotion Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo Japan Exclusive Daiichi Sankyo Beginning January 1, 2016, while major European markets continue to be a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets. The economic results for the major European markets continue to be shared in the same proportion as they were previously. The parties share approximately 50 /50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we continue to produce the finished product for our exclusive and co-promotion territories, including the major European markets. We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Beginning January 1, 2016, any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017. The following table summarizes our revenue recognized with respect to Effient: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenue $ 55.9 $ 127.7 $ 326.6 $ 394.3 Olumiant ® We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib (trade name Olumiant), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis and atopic dermatitis in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In the first quarter of 2016, we incurred milestone-related expenses of $55.0 million in connection with regulatory submissions in the U.S. and Europe, which were recorded as research and development expense. We capitalized as intangible assets $65.0 million in the first quarter of 2017 and $15.0 million in the third quarter of 2017 of milestones in connection with regulatory approvals in Europe and Japan, respectively, which are being amortized to cost of sales over the term of the collaboration. As of September 30, 2017 , Incyte is eligible to receive up to $280.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones, of which $100.0 million relates to the U.S. regulatory decision for a first indication. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones. Tanezumab We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. Following the U.S. Food and Drug Administration's (FDA's) decision in March 2015 to lift the partial clinical hold on tanezumab, certain Phase III trials resumed in July 2015. Upon the FDA's lifting of the partial clinical hold and the decision to continue the collaboration with Pfizer, we paid an upfront fee of $200.0 million , which was expensed as acquired IPR&D. As of September 30, 2017 , Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Lanabecestat We have a collaboration agreement with AstraZeneca for the worldwide co-development and co-commercialization of AstraZeneca’s lanabecestat, an oral beta-secretase cleaving enzyme (BACE) inhibitor being investigated for the potential treatment of Alzheimer’s disease. We are responsible for leading development efforts, while AstraZeneca will be responsible for manufacturing efforts. If successful, both parties will take joint responsibility for commercialization. Under the agreement, both parties share equally in the ongoing development costs and, if successful, in gross margins and certain other costs associated with commercialization of the molecule. As a result of the molecule moving into Phase III testing in April 2016, we incurred a $100.0 million developmental milestone, which was recorded as research and development expense in the second quarter of 2016. In July 2017, as a result of the outcome of an interim analysis, we incurred a $50.0 million developmental milestone, which was recorded as research and development expense in the third quarter of 2017. As of September 30, 2017 , AstraZeneca is eligible to receive up to $300.0 million of additional payments from us contingent upon the achievement of certain development and success-based regulatory milestones.

Asset Impairment, Restructuring

Asset Impairment, Restructuring, and Other Special Charges	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Asset Impairment, Restructuring, and Other Special Charges	Asset Impairment, Restructuring, and Other Special Charges The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. Three Months Ended Nine Months Ended 2017 2016 2017 2016 Severance: Human pharmaceutical products $ 165.7 $ — $ 277.1 $ — Animal health products 5.8 8.3 62.1 37.0 Total severance 171.5 8.3 339.2 37.0 Asset impairment and other special charges: Human pharmaceutical products 25.0 — 25.0 — Animal health products 210.0 37.2 306.2 197.9 Total asset impairment and other special charges 235.0 37.2 331.2 197.9 Total asset impairment, restructuring, and other special charges $ 406.5 $ 45.5 $ 670.4 $ 234.9 Severance costs recognized during the three months ended September 30, 2017 were incurred as a result of actions taken to reduce our cost structure. Severance costs recognized during the nine months ended September 30, 2017 were incurred as a result of actions taken to reduce our cost structure, as well as the integration of Novartis Animal Health (Novartis AH). Severance costs recognized during the three and nine months ended September 30, 2016 related primarily to the integration of Novartis AH. Severance costs recognized during the nine months ended September 30, 2016 also related to our decision to close an animal health manufacturing plant in Ireland. Substantially all of the severance costs incurred during the three and nine months ended September 30, 2017 are expected to be paid in the next 12 months. Substantially all of the asset impairment and other special charges related to animal health products recognized during the three months ended September 30, 2017 related to lower projected revenue for Posilac ® (rbST). The company is exploring strategic options for Posilac, including seeking a buyer for the molecule and its Augusta manufacturing site. The assets associated with Posilac were written down to their fair values, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Posilac subsequent to the impairment charge are not material. Other asset impairment and other special charges recognized during the three months ended September 30, 2017 related to exit costs associated with site closures. Asset impairment and other special charges recognized during the nine months ended September 30, 2017 resulted primarily from charges associated with the Posilac impairment, integration costs of Novartis AH, as well as asset impairments due to site closures. Asset impairment and other special charges recognized during the three months ended September 30, 2016 related primarily to integration costs related to our acquisition of Novartis AH. Asset impairment and other special charges recognized during the nine months ended September 30, 2016 resulted primarily from $87.2 million of asset impairment and other charges related to our decision to close an animal health manufacturing plant in Ireland. The manufacturing plant was written down to its estimated fair value, which was based primarily on recent sales of similar assets. The remaining asset impairment and other special charges recognized during the nine months ended September 30, 2016 consisted of integration costs related to our acquisition of Novartis AH. In September 2017, we announced plans to reduce our cost structure by streamlining our operations, including a U.S. voluntary early retirement program. In addition to the asset impairment, restructuring, and other special charges discussed above that were incurred during the three months ended September 30, 2017, we expect to incur additional charges of approximately $800 million in the fourth quarter of 2017 related to these plans. The fourth quarter charge could vary depending on the composition of participants within the U.S. voluntary early retirement program, as well as other actions taken to improve our cost structure.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2017 , we had outstanding foreign currency forward commitments to purchase 502.9 million U.S. dollars and sell 422.1 million euro, commitments to purchase 735.7 million euro and sell 878.1 million U.S. dollars, commitments to purchase 428.4 million U.S. dollars and sell 47.90 billion Japanese yen, commitments to purchase 295.9 million British pounds and sell 334.8 million euro, and commitments to purchase 287.3 million U.S. dollars and sell 212.2 million British pounds, which will all settle within 30 days . Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $3.67 billion and $3.34 billion as of September 30, 2017 and December 31, 2016 , respectively, and have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations. Our cross-currency interest rate swaps that convert a portion of our U.S. dollar-denominated floating rate debt to euro-denominated floating rate debt have also been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September 30, 2017 , substantially all of our total long-term debt is at a fixed rate. We have converted approximately 30 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. In May 2017, we issued $750.0 million of 2.35 percent fixed-rate notes due in May 2022, $750.0 million of 3.10 percent fixed-rate notes due in May 2027, and $750.0 million of 3.95 percent fixed-rate notes due in May 2047, with interest to be paid semi-annually. We are using the net proceeds of $2.23 billion from the sale of these notes for general corporate purposes, which may include the repayment of notes due in 2018 and 2019. Prior to such uses, we may temporarily invest the net proceeds in investment securities. In May 2016, we issued Swiss franc-denominated notes consisting of Fr.200.0 million of 0.00 percent fixed-rate notes due in May 2018, Fr.600.0 million of 0.15 percent fixed-rate notes due in May 2024, and Fr.400.0 million of 0.45 percent fixed-rate notes due in May 2028, with interest to be paid annually. We are using the net cash proceeds of the offering of $1.21 billion for general corporate purposes, which included the repayment at maturity of certain of our U.S. dollar denominated fixed-rate notes due March 2017. The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations The following effects of risk-management instruments were recognized in other–net, (income) expense: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Fair value hedges: Effect from hedged fixed-rate debt $ (4.0 ) $ (18.8 ) $ 3.6 $ 92.4 Effect from interest rate contracts 4.0 18.8 (3.6 ) (92.4 ) Cash flow hedges: Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 3.7 3.8 11.1 11.2 Net losses on foreign currency exchange contracts not designated as hedging instruments 16.3 1.4 79.2 105.6 During the nine months ended September 30, 2017 and 2016 , net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material. The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss) The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net investment hedges: Foreign currency-denominated notes $ (58.7 ) $ (37.0 ) $ (332.0 ) $ (80.0 ) Cross-currency interest rate swaps (38.2 ) (4.1 ) (95.8 ) 2.2 Foreign currency exchange contracts — — — 31.9 Cash flow hedges: Forward-starting interest rate swaps — — 13.0 (3.4 ) During the next 12 months, we expect to reclassify $14.7 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. Fair Value of Financial Instruments The following tables summarize certain fair value information at September 30, 2017 and December 31, 2016 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2017 Cash equivalents $ 2,066.7 $ 2,066.7 $ 1,611.0 $ 455.7 $ — $ 2,066.7 Short-term investments: U.S. government and agency securities $ 742.2 $ 742.7 $ 742.2 $ — $ — $ 742.2 Corporate debt securities 2,322.9 2,322.4 — 2,322.9 — 2,322.9 Asset-backed securities 149.8 149.8 — 149.8 — 149.8 Other securities 3.9 3.9 — 3.9 — 3.9 Short-term investments $ 3,218.8 Noncurrent investments: U.S. government and agency securities $ 411.7 $ 415.3 $ 411.7 $ — $ — $ 411.7 Corporate debt securities 3,913.2 3,903.8 — 3,913.2 — 3,913.2 Mortgage-backed securities 165.1 166.0 — 165.1 — 165.1 Asset-backed securities 638.8 639.2 — 638.8 — 638.8 Other securities 130.7 75.5 — — 130.7 130.7 Marketable equity securities 344.7 127.5 344.7 — — 344.7 Cost and equity method investments (2) 544.5 Noncurrent investments $ 6,148.7 December 31, 2016 Cash equivalents $ 2,986.8 $ 2,986.8 $ 2,699.4 $ 287.4 $ — $ 2,986.8 Short-term investments: U.S. government and agency securities $ 232.5 $ 232.6 $ 232.5 $ — $ — $ 232.5 Corporate debt securities 1,219.2 1,219.1 — 1,219.2 — 1,219.2 Asset-backed securities 4.3 4.3 — 4.3 — 4.3 Other securities 0.5 0.5 — 0.5 — 0.5 Short-term investments $ 1,456.5 Noncurrent investments: U.S. government and agency securities $ 318.9 $ 323.8 $ 318.9 $ — $ — $ 318.9 Corporate debt securities 3,062.2 3,074.3 — 3,062.2 — 3,062.2 Mortgage-backed securities 183.1 185.4 — 183.1 — 183.1 Asset-backed securities 502.7 503.5 — 502.7 — 502.7 Other securities 153.7 77.6 — — 153.7 153.7 Marketable equity securities 418.2 91.9 418.2 — — 418.2 Cost and equity method investments (2) 568.7 Noncurrent investments $ 5,207.5 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) Fair value disclosures are not applicable for cost method and equity method investments. Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term commercial paper borrowings September 30, 2017 $ (2,526.0 ) $ — $ (2,523.7 ) $ — $ (2,523.7 ) December 31, 2016 (1,299.3 ) — (1,299.3 ) — (1,299.3 ) Long-term debt, including current portion September 30, 2017 $ (10,938.7 ) $ — $ (11,448.4 ) $ — $ (11,448.4 ) December 31, 2016 (9,005.9 ) — (9,419.1 ) — (9,419.1 ) Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2017 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 2.0 $ — $ 2.0 $ — $ 2.0 Sundry 43.0 — 43.0 — 43.0 Other current liabilities (0.4 ) — (0.4 ) — (0.4 ) Other noncurrent liabilities (1.8 ) — (1.8 ) — (1.8 ) Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities (43.4 ) — (43.4 ) — (43.4 ) Other noncurrent liabilities (20.5 ) — (20.5 ) — (20.5 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 21.0 — 21.0 — 21.0 Other current liabilities (13.9 ) — (13.9 ) — (13.9 ) Contingent consideration liabilities (1) : Other current liabilities (201.8 ) — — (201.8 ) (201.8 ) Other noncurrent liabilities (92.2 ) — — (92.2 ) (92.2 ) December 31, 2016 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 2.4 $ — $ 2.4 $ — $ 2.4 Sundry 37.0 — 37.0 — 37.0 Other noncurrent liabilities (0.5 ) — (0.5 ) — (0.5 ) Cross-currency interest rate contracts designated as net investment hedges: Sundry 31.4 — 31.4 — 31.4 Foreign exchange contracts not designated as hedging instruments: Other receivables 31.8 — 31.8 — 31.8 Other current liabilities (21.7 ) — (21.7 ) — (21.7 ) Contingent consideration liabilities (1) : Other current liabilities (215.9 ) — — (215.9 ) (215.9 ) Other noncurrent liabilities (242.6 ) — — (242.6 ) (242.6 ) (1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4. Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material. We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of cost and equity method investments are not readily available. Contingent consideration liabilities primarily include contingent consideration related to Erbitux, for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America through September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The decrease in the fair value of the contingent consideration liabilities during the nine months ended September 30, 2017 was due primarily to cash payments of $151.3 million related to Erbitux. The change in the fair value of the contingent consideration liabilities recognized in earnings during the three and nine months ended September 30, 2017 and 2016 due to changes in time value of money was not material. The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2017 : Maturities by Period Total Less Than 1 Year 1-5 Years 6-10 Years More Than 10 Years Fair value of debt securities $ 8,343.7 $ 3,214.9 $ 4,795.2 $ 122.4 $ 211.2 A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: September 30, 2017 December 31, 2016 Unrealized gross gains $ 259.7 $ 352.6 Unrealized gross losses 27.2 34.1 Fair value of securities in an unrealized gain position 3,400.7 1,869.7 Fair value of securities in an unrealized loss position 4,013.9 3,262.3 We periodically assess our investment securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses in the three and nine months ended September 30, 2017 . Other-than-temporary impairment losses recognized during the three and nine months ended September 30, 2016 were $11.4 million and $53.0 million , respectively. For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. For equity securities, factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, our intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, and general market conditions and industry specific factors. As of September 30, 2017 , the securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 95 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September 30, 2017 , we do not intend to sell, and it is not more likely than not that we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities. Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Proceeds from sales $ 951.5 $ 926.3 $ 3,003.0 $ 2,503.4 Realized gross gains on sales 9.0 12.8 82.9 18.0 Realized gross losses on sales 0.8 1.3 3.2 11.7 Realized gains and losses on sales of investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Accounts Receivable Factoring Arrangements We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $678.9 million and $661.6 million of accounts receivable as of September 30, 2017 and December 31, 2016 , respectively, under these factoring arrangements. The cost of factoring such accounts receivable on our consolidated condensed results of operations for the nine months ended September 30, 2017 and 2016 was not material.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Shareholders’ Equity During the nine months ended September 30, 2017 and 2016 , we repurchased $259.9 million and $300.1 million of shares, respectively, associated with our $5.00 billion share repurchase program announced in October 2013. A payment of $60.0 million was made in the fourth quarter of 2016 for shares repurchased in 2017. As of September 30, 2017 , there were $2.15 billion of shares remaining in that program.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rates were 6.1 percent and 24.1 percent for the three and nine months ended September 30, 2017 , respectively, compared with 19.9 percent and 20.8 percent for the same respective periods of 2016 . The decrease in the effective tax rate for the third quarter of 2017 is primarily due to the income tax benefit of acquired IPR&D charges and asset impairment, restructuring, and other special charges. The increase in the effective tax rate for the first nine months of 2017 is primarily due to the non-tax deductible $857.6 million acquired IPR&D charge for the acquisition of CoLucid, partially offset by the income tax benefit of acquired IPR&D charges and asset impairment, restructuring, and other special charges. During the first quarter of 2016, we completed and effectively settled the U.S. examination of tax years 2010 - 2012 . As a result of this resolution, our gross uncertain tax positions were reduced by approximately $140 million , and our consolidated condensed results of operations benefited from an immaterial reduction in income tax expense. During 2016, we made cash payments of approximately $150 million related to tax years 2010 - 2012 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2013 - 2015 began in 2016 and is ongoing. The resolution of matters in this audit period will likely extend beyond the next 12 months.

Retirement Benefits

Retirement Benefits	9 Months Ended
	Sep. 30, 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Retirement Benefits	Retirement Benefits Net pension and retiree health benefit (income) cost included the following components: Defined Benefit Pension Plans Three Months Ended Nine Months Ended 2017 2016 2017 2016 Components of net periodic benefit cost: Service cost $ 86.0 $ 70.2 $ 251.6 $ 212.2 Interest cost 103.6 104.2 309.2 314.4 Expected return on plan assets (196.4 ) (187.6 ) (585.7 ) (566.7 ) Amortization of prior service cost 1.4 2.9 4.3 8.6 Recognized actuarial loss 72.5 71.0 215.6 213.4 Net periodic benefit cost $ 67.1 $ 60.7 $ 195.0 $ 181.9 Retiree Health Benefit Plans Three Months Ended Nine Months Ended 2017 2016 2017 2016 Components of net periodic benefit income: Service cost $ 11.6 $ 9.7 $ 34.8 $ 29.3 Interest cost 13.2 13.0 39.6 39.0 Expected return on plan assets (40.2 ) (37.6 ) (120.6 ) (112.7 ) Amortization of prior service benefit (22.5 ) (21.5 ) (67.5 ) (64.3 ) Recognized actuarial loss 4.6 5.2 13.8 15.5 Net periodic benefit income $ (33.3 ) $ (31.2 ) $ (99.9 ) $ (93.2 ) We have contributed approximately $30 million required to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the nine months ended September 30, 2017 . Additional discretionary funding in the aggregate was not material during the nine months ended September 30, 2017 . During the remainder of 2017 , we expect to make contributions to our defined benefit pension and retiree health benefit plans of approximately $10 million to satisfy minimum funding requirements. No additional discretionary funding for the remainder of 2017 has been approved at this time.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta ® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Alimta Patent Litigation and Administrative Proceedings A number of generic manufacturers are seeking approvals in various countries to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenue for the product in the relevant market. U.S. Patent Litigation and Administrative Proceedings We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). More than 10 Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP). These companies have also alleged the patent is invalid. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP and two other defendants seeking rulings that the U.S. vitamin regimen patent is valid and infringed (the Teva/APP litigation). A trial occurred in August 2013; the sole issue before the district court at that time was to determine patent validity. In March 2014, the district court ruled that the asserted claims of the vitamin regimen patent are valid. The U.S. District Court for the Southern District of Indiana held a hearing on the issue of infringement in May 2015. In September 2015, the district court ruled that the vitamin regimen patent would be infringed by the generic challengers' proposed products. Teva and APP appealed all of the district court’s substantive decisions. In January 2017, the U.S. Court of Appeals for the Federal Circuit affirmed the district court’s decisions concerning validity and infringement. The defendants did not file for writ of certiorari with the U.S. Supreme Court, making the Court of Appeal's decision final. From 2012 through 2017, we filed similar lawsuits against other ANDA defendants seeking a ruling that our patents are valid and infringed. As a result of the completion of the Teva/APP litigation, the U.S. District Court for the Southern District of Indiana has entered a judgment against five companies. Cases remain pending against an additional six ANDA defendants. We have filed lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Dr. Reddy's Laboratories (Dr. Reddy's), Hospira, Inc. (Hospira), Apotex, and Actavis LLC in response to their alternative forms of pemetrexed products. In November 2017, the court is expected to hold a hearing on a motion for summary judgment filed by Dr. Reddy's. If that motion is denied, trial is expected in early 2018. We have also filed a lawsuit against Eagle Pharmaceuticals (Eagle) in the U.S. District Court for Delaware. Eagle has filed suit against us in U.S. District Court of New Jersey alleging violations of federal competition law relating to its application for an alternative salt form of pemetrexed (the active ingredient in Alimta). In June 2016, the U.S. Patent and Trademark Office (USPTO) granted petitions by Neptune Generics, LLC and Sandoz Inc. seeking inter partes review (IPR) of our vitamin regimen patent. Several additional generic companies filed petitions and joined these proceedings. In October 2017, the USPTO ruled in our favor, finding that the claims of the vitamin regimen patent are valid. The generic companies which filed petitions with the USPTO may appeal these rulings to the U.S. Court of Appeals for the Federal Circuit. European Patent Litigation and Administrative Proceedings In the United Kingdom (U.K.), Actavis Group ehf and other Actavis companies (collectively, Actavis) filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed would not infringe the vitamin regimen patents for Alimta in the U.K., Italy, France, and Spain. In trial court and court of appeal decisions, the alternative salt forms were found to indirectly infringe the Alimta vitamin regimen patent when reconstituted in saline, but not to directly infringe the patents as an equivalent. We appealed. In July 2017, the U.K. Supreme Court ruled that Actavis’s products directly infringe our vitamin regimen patents in the U.K., Italy, France, and Spain. The U.K. Supreme Court also affirmed an earlier finding by the U.K. Court of Appeal that the Alimta vitamin regimen patent would be indirectly infringed by commercialization of Actavis’s products diluted in saline. We intend to pursue Actavis and others that launched at risk for damages. Actavis sought a declaration of non-infringement from the U.K. High Court for a different proposed product diluted in dextrose solution. In February 2016, the trial court ruled that Actavis’ commercialization of this product would not infringe the patent in the U.K., Italy, France, and Spain. We are still seeking to appeal this ruling for procedural purposes, although it has now been superseded by the U.K. Supreme Court's recent decision. We commenced separate infringement proceedings against certain Actavis companies in Germany. In April 2014, the German trial court ruled in our favor. The defendants appealed and the German Court of Appeal overturned the trial court and ruled that our vitamin regimen patent in Germany would not be infringed by a dipotassium salt form of pemetrexed. In June 2016, the German Federal Supreme Court granted our appeal, vacating the prior decision denying infringement, and returned the case to the German Court of Appeal to reconsider issues relating to infringement. In separate proceedings, in May 2016 and June 2016, the German courts confirmed preliminary injunctions against Hexal AG (Hexal), which had stated its intention to launch a generic disodium salt product diluted in saline solution, and ratiopharm GmbH (ratiopharm), a subsidiary of Teva, which had stated its intention to launch a proposed alternative salt form of pemetrexed product diluted in dextrose solution. The German Court of Appeal affirmed the preliminary injunction against ratiopharm in May 2017. The preliminary injunctions against both Hexal and ratiopharm will remain in place pending the outcome of the cases on the merits. In late 2016, the German courts issued preliminary injunctions against two other companies that had stated their intentions to launch a proposed alternative salt form of pemetrexed product diluted in dextrose solution. Hexal and Stada Arzneimittel AG have separately challenged the validity of our vitamin regimen patent before the German Federal Patent court. The hearing will take place in mid-2018. We do not anticipate any generic entry into the German market at least until the German Court of Appeal considers the issues remanded by the German Federal Supreme Court in the proceedings against Actavis, or if the injunctions are lifted. Additional legal proceedings are ongoing in various national courts of other European countries. We are aware that generic competitors have received approval to market generic versions of pemetrexed in major European markets, and that a generic product is currently on the market in at least one major European market. In light of the U.K. Supreme Court's judgment finding infringement in the U.K., Italy, France, and Spain, Actavis has withdrawn its previously launched-at-risk generic products from these markets. We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets. Japanese Administrative Proceedings Three separate sets of demands for invalidation of our two vitamin regimen patents, involving several companies, were filed with the Japanese Patent Office (JPO). In November 2015, the JPO issued written decisions in the invalidation trials initiated by Sawai Pharmaceutical Co., Ltd. (Sawai), which had been joined by three other companies, upholding both vitamin regimen patents. In February 2017, the Japan Intellectual Property High Court confirmed the decisions of the JPO and ruled in our favor in the invalidation trials initiated by Sawai. The Japan Intellectual Property High Court’s decisions regarding the demands initiated by Sawai are now final. In May 2017, the JPO resumed one of the two remaining sets of demands, brought by Nipro Corporation. We expect a decision from the JPO on those demands in the first half of 2018. The other set of demands, brought by Hospira and Hospira Japan remain suspended. If upheld through all challenges, these patents provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta were approved in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval. Effient Patent Litigation and Administrative Proceedings We, along with Daiichi Sankyo, Daiichi Sankyo, Inc., and Ube Industries (Ube) are engaged in U.S. patent litigation involving Effient brought pursuant to procedures set out in the Hatch-Waxman Act. More than 10 different companies have submitted ANDAs seeking approval to market generic versions of Effient prior to the expiration of Daiichi Sankyo’s and Ube’s patents (expiring in 2023) covering methods of using Effient with aspirin, and alleging the patents are invalid. One of these ANDAs also alleged that the compound patent for Effient (which expired in April 2017) was invalid. Beginning in March 2014, we filed lawsuits in the U.S. District Court for the Southern District of Indiana against these companies, seeking a ruling that the patents are valid and infringed. Following the settlement related to the compound patent challenge, generic products launched in the U.S. in the third quarter of 2017. The remaining cases have been consolidated and stayed. The entry of generic competition has caused a rapid and severe decline in revenue for the product. In 2015, several generic pharmaceutical companies filed petitions with the USPTO, requesting IPR of the method-of-use patents. In September 2016, the USPTO determined that the method-of-use patents are invalid. Daiichi Sankyo and Ube have appealed these decisions to the U.S. Court of Appeals for the Federal Circuit. We expect a final decision in late 2017. The consolidated lawsuit is currently stayed with respect to all parties pending the outcome of this appeal. We believe the Effient method-of-use patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. Actos ® Product Liability Litigation We were named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in approximately 6,700 product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until 2006. In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. Almost all of these cases were included as part of a resolution program announced by Takeda in April 2015 in which Takeda agreed to pay approximately $2.4 billion to resolve the vast majority of the U.S. product liability lawsuits involving Actos. Although the vast majority of U.S. product liability lawsuits involving Actos are included in the resolution program, there may be additional cases pending against Takeda and us following completion of the resolution program. We are also named along with Takeda as a defendant in three purported product liability class actions in Canada related to Actos, including one in Ontario ( Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. and Carrier et al. v. Eli Lilly et al. ), one in Quebec ( Whyte et al. v. Eli Lilly et al. ), and one in Alberta ( Epp v. Takeda Canada et al. ). We promoted Actos in Canada until 2009. We believe these lawsuits are without merit, and we and Takeda are prepared to defend against them vigorously. Cymbalta ® Product Liability Litigation In October 2012, we were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called Strafford et al. v. Eli Lilly and Company ) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. In December 2014, the district court denied the plaintiffs' motion for class certification. Plaintiffs filed a petition with the U.S. Court of Appeals for the Ninth Circuit requesting permission to file an interlocutory appeal of the denial of class certification, which was denied. Plaintiffs filed a second motion for certification under the consumer protection acts of New York and Massachusetts. The district court denied that motion for class certification in July 2015. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In June 2017, we moved to dismiss the appeal for lack of jurisdiction based on the U.S. Supreme Court's recent decision in Microsoft v. Baker . In October 2017, the U.S. Court of Appeals for the Ninth Circuit granted our motion. We are named in approximately 140 lawsuits involving approximately 1,470 plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. These include approximately 40 individual and multi-plaintiff cases filed in California state court, centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against approximately five plaintiffs. We believe all these Cymbalta lawsuits and claims are without merit. We have reached a settlement framework which provides for a comprehensive resolution of nearly all of these personal injury claims, filed or unfiled, alleging injuries from discontinuing treatment with Cymbalta. There can be no assurances, however, that a final settlement will be reached. Brazil–Employee Litigation Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. While we cannot currently estimate the range of reasonably possible financial losses that could arise in the event we do not ultimately prevail in the litigation, the judge has estimated the total financial impact of the ruling to be approximately 1.0 billion Brazilian real (approximately $315 million as of September 30, 2017 ) plus interest. We strongly disagree with the decision and filed an appeal in May 2014. We expect a ruling on this appeal before the end of the year. We are also named in approximately 40 lawsuits filed in the same court by individual former employees making similar claims. Lilly Brasil and Elanco Quimica Ltda. have also been named in a lawsuit in 15th Region in the Labor Court of Paulinia, State of Sao Paulo, involving approximately 305 individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to employees, former employees, and their dependents. In June 2017, the court denied the plaintiffs' request for a preliminary injunction. In September 2017, the court dismissed all claims except the one filed by the first named plaintiff. The other plaintiffs have filed a motion for clarification, which may lead to the filing of an appeal. We believe all of these lawsuits are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2017 and 2016 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2017 $ (1,349.4 ) $ 153.2 $ (3,348.5 ) $ (197.6 ) $ (4,742.3 ) Other comprehensive income (loss) before reclassifications 135.8 33.9 (28.7 ) — 141.0 Net amount reclassified from accumulated other comprehensive loss 8.1 (23.9 ) 40.1 2.4 26.7 Net other comprehensive income (loss) 143.9 10.0 11.4 2.4 167.7 Balance at September 30, 2017 (2) $ (1,205.5 ) $ 163.2 $ (3,337.1 ) $ (195.2 ) $ (4,574.6 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2016 $ (1,273.0 ) $ 36.8 $ (2,919.1 ) $ (215.9 ) $ (4,371.2 ) Other comprehensive income (loss) before reclassifications 5.8 48.9 18.7 — 73.4 Net amount reclassified from accumulated other comprehensive loss — (0.4 ) 38.0 2.5 40.1 Net other comprehensive income (loss) 5.8 48.5 56.7 2.5 113.5 Balance at September 30, 2016 (2) $ (1,267.2 ) $ 85.3 $ (2,862.4 ) $ (213.4 ) $ (4,257.7 ) The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2017 and 2016 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2017 (1) $ (1,867.3 ) $ 224.0 $ (3,371.6 ) $ (210.9 ) $ (5,225.8 ) Other comprehensive income (loss) before reclassifications 653.7 9.6 (83.3 ) 8.4 588.4 Net amount reclassified from accumulated other comprehensive loss 8.1 (70.4 ) 117.8 7.3 62.8 Net other comprehensive income (loss) 661.8 (60.8 ) 34.5 15.7 651.2 Balance at September 30, 2017 (2) $ (1,205.5 ) $ 163.2 $ (3,337.1 ) $ (195.2 ) $ (4,574.6 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2016 (1) $ (1,360.2 ) $ 10.1 $ (3,012.1 ) $ (218.5 ) $ (4,580.7 ) Other comprehensive income (loss) before reclassifications 18.5 61.9 39.2 (2.2 ) 117.4 Net amount reclassified from accumulated other comprehensive loss 74.5 13.3 110.5 7.3 205.6 Net other comprehensive income (loss) 93.0 75.2 149.7 5.1 323.0 Balance at September 30, 2016 (2) $ (1,267.2 ) $ 85.3 $ (2,862.4 ) $ (213.4 ) $ (4,257.7 ) (1) Accumulated other comprehensive loss as of January 1, 2017 consists of $5,274.0 million of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to non-controlling interest. The accumulated other comprehensive loss attributable to non-controlling interest as of January 1, 2016 is immaterial. (2) Accumulated other comprehensive loss as of September 30, 2017 consists of $4,609.4 million of accumulated other comprehensive loss attributable to controlling interest and $34.8 million of accumulated other comprehensive income attributable to non-controlling interest. The accumulated other comprehensive loss attributable to non-controlling interest as of September 30, 2016 is immaterial. The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows: Three Months Ended Nine Months Ended Tax benefit (expense) 2017 2016 2017 2016 Foreign currency translation gains/losses $ 33.9 $ 14.4 $ 149.7 $ 16.1 Unrealized net gains/losses on securities (4.2 ) (26.1 ) 25.4 (40.5 ) Defined benefit pension and retiree health benefit plans (9.4 ) (9.5 ) (24.0 ) (57.0 ) Effective portion of cash flow hedges (1.3 ) (1.3 ) (8.4 ) (2.7 ) Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ 19.0 $ (22.5 ) $ 142.7 $ (84.1 ) Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations. Reclassifications out of accumulated other comprehensive loss were as follows: Details about Accumulated Other Comprehensive Loss Components Three Months Ended Nine Months Ended Affected Line Item in the Consolidated Condensed Statements of Operations 2017 2016 2017 2016 Amortization of retirement benefit items: Prior service benefits, net $ (21.1 ) $ (18.6 ) $ (63.2 ) $ (55.7 ) (1) Actuarial losses, net 77.1 76.2 229.4 228.9 (1) Total before tax 56.0 57.6 166.2 173.2 Tax benefit (15.9 ) (19.6 ) (48.4 ) (62.7 ) Income taxes Net of tax 40.1 38.0 117.8 110.5 Unrealized gains/losses on available-for-sale securities: Realized gains, net before tax (36.7 ) (12.0 ) (108.2 ) (6.8 ) Other–net, (income) expense Impairment losses — 11.4 — 27.3 Other–net, (income) expense Total before tax (36.7 ) (0.6 ) (108.2 ) 20.5 Tax (benefit) expense 12.8 0.2 37.8 (7.2 ) Income taxes Net of tax (23.9 ) (0.4 ) (70.4 ) 13.3 Other, net of tax (2) 10.5 2.5 15.4 81.8 Other–net, (income) expense Total reclassifications for the period (net of tax) $ 26.7 $ 40.1 $ 62.8 $ 205.6 (1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 9). (2) Amount for the nine months ended September 30, 2016 included primarily $74.5 million of foreign currency translation losses.

Other-Net, (Income) Expense

Other-Net, (Income) Expense	9 Months Ended
	Sep. 30, 2017
Nonoperating Income (Expense) [Abstract]
Other - Net, (Income) Expense	Other–Net, (Income) Expense Other–net, (income) expense consisted of the following: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Interest expense $ 61.9 $ 47.2 $ 162.1 $ 133.8 Interest income (45.1 ) (29.1 ) (114.6 ) (76.8 ) Venezuela charge — — — 203.9 Other income (2.9 ) (45.3 ) (44.8 ) (160.3 ) Other–net, (income) expense $ 13.9 $ (27.2 ) $ 2.7 $ 100.6 Due to the financial crisis in Venezuela and the significant deterioration of the bolívar, we changed the exchange rate used to translate the assets and liabilities of our subsidiaries in Venezuela which resulted in a first quarter of 2016 charge of $203.9 million . Prior to this change, we used the Supplementary Foreign Currency Administration System (SICAD) rate; however, this official rate was discontinued in the first quarter of 2016. After considering several factors, including the future uncertainty of the Venezuelan economy, published exchange rates, and the limited amount of foreign currency exchanged, we changed to the Divisa Complementaria (DICOM) rate.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Information	Segment Information We have two operating segments—human pharmaceutical products and animal health products. Our operating segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. Three Months Ended Nine Months Ended 2017 2016 2017 2016 Segment revenue—to unaffiliated customers: Human pharmaceutical products: Endocrinology: Humalog ® $ 696.2 $ 640.8 $ 2,083.0 $ 1,949.0 Trulicity ® 527.7 243.6 1,380.8 588.5 Forteo ® 441.7 391.2 1,235.8 1,077.5 Humulin ® 300.5 322.0 972.8 1,010.6 Trajenta 153.3 115.4 408.2 330.8 Other Endocrinology 441.3 262.8 1,094.4 734.5 Total Endocrinology 2,560.7 1,975.8 7,175.0 5,690.9 Oncology: Alimta 514.5 570.4 1,537.3 1,741.7 Cyramza ® 196.0 159.0 553.5 437.0 Erbitux 163.5 184.6 477.0 533.3 Other Oncology 83.6 33.3 232.7 100.3 Total Oncology 957.6 947.3 2,800.5 2,812.3 Cardiovascular: Cialis ® 564.9 588.2 1,725.7 1,795.3 Effient 55.9 127.7 326.6 394.3 Other Cardiovascular 42.1 57.6 120.2 165.4 Total Cardiovascular 662.9 773.5 2,172.5 2,355.0 Neuroscience: Cymbalta (1) 183.2 313.5 564.4 748.7 Strattera ® 137.1 198.8 519.9 611.5 Zyprexa ® 140.6 148.9 428.9 572.3 Other Neuroscience 46.8 47.3 160.5 137.4 Total Neuroscience 507.7 708.5 1,673.7 2,069.9 Immunology: Taltz ® 151.3 32.5 386.7 51.9 Other Immunology 16.3 — 22.9 — Total Immunology 167.6 32.5 409.6 51.9 Other pharmaceuticals 60.9 47.9 184.5 161.1 Total human pharmaceutical products 4,917.4 4,485.5 14,415.8 13,141.1 Animal health products 740.6 706.2 2,294.8 2,320.5 Revenue $ 5,658.0 $ 5,191.7 $ 16,710.6 $ 15,461.6 Three Months Ended Nine Months Ended 2017 2016 2017 2016 Segment profits: Human pharmaceutical products $ 1,242.5 $ 1,089.0 $ 3,765.7 $ 2,975.3 Animal health products 121.9 104.9 422.6 464.3 Total segment profits $ 1,364.4 $ 1,193.9 $ 4,188.3 $ 3,439.6 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 1,364.4 $ 1,193.9 $ 4,188.3 $ 3,439.6 Other profits (losses): Acquired in-process research and development (Note 3) (205.0 ) — (1,062.6 ) — Amortization of intangible assets (155.8 ) (177.7 ) (510.0 ) (518.8 ) Asset impairment, restructuring, and other special charges (Note 5) (406.5 ) (45.5 ) (670.4 ) (234.9 ) Inventory fair value adjustment related to BIVIVP (Note 3) (5.5 ) — (32.0 ) — Venezuela charge (Note 12) — — — (203.9 ) Consolidated income before taxes $ 591.6 $ 970.7 $ 1,913.3 $ 2,482.0 Numbers may not add due to rounding. (1) Cymbalta revenues include reductions to the reserve for expected product returns of approximately $145 million and $175 million during the three and nine months ended September 30, 2016 , respectively. For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.

Acquisitions (Policies)

Acquisitions (Policies)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Business Combinations Policy	Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition are included in our consolidated condensed financial statements from the date of acquisition. Upon acquisition, the acquired in-process research and development (IPR&D) charges related to these products were immediately expensed because the products had no alternative future use.

Financial Instruments (Policies

Financial Instruments (Policies)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Description of Derivative Risk Management Policy	Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.

Implementation of New Accountin

Implementation of New Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table provides a brief description of accounting standards that have not yet been adopted and could have a material effect on our financial statements: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers This standard will replace existing revenue recognition standards and will require entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach. This standard is effective January 1, 2018, and we will adopt on that date. We are in the process of completing our evaluation of the impact of adopting the standard. We have identified two revenue streams from our contracts with customers: 1) product sales, which represented 96 percent of our 2016 consolidated revenue and 2) licensing and other arrangements, which represented 4 percent of our 2016 consolidated revenue. We are also evaluating the new disclosures required by the standard to determine what additional information will need to be disclosed. Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities This standard will require entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. This standard is effective January 1, 2018, and we will adopt on that date. We are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption. Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2016-02, Leases This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. This standard requires a modified retrospective approach to adoption. This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on January 1, 2019. We are in the process of determining the impact on our consolidated financial statements. Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory This standard will require entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified This standard is effective January 1, 2018, and we will adopt on that date. We are continuing to assess the potential impact of this standard on our consolidated financial statements and currently estimate that the cumulative effect of initially applying the standard would result in an increase to deferred tax assets and the opening balance of retained earnings of approximately $2 billion on January 1, 2018. This estimate is subject to change based upon intra-entity transfers of assets other than inventory over the remainder of 2017 and ongoing assessments of the future deductibility and realizability of the deferred tax assets that would result from implementation. Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Currently, the costs of the other components along with the service cost component are classified based upon the function of the employee. This standard will require entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost will be presented separately from the line items that include the service cost component. When applicable, the service cost component will be the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. This standard is effective January 1, 2018, and we will adopt this standard on that date. Upon adoption of this standard, pension and postretirement benefit cost components other than service costs will be presented in other–net, (income) expense. We do not expect the application of the new standard to have a material impact on consolidated net income either at initial implementation or on an ongoing basis.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2017
Business Acquisition [Line Items]
Schedule of Research and Development Assets Acquired Other than Through Business Combination	The following table and narrative summarizes our asset acquisitions during the nine months ended September 30, 2017 . There was no asset acquisition which resulted in acquired IPR&D expense during the nine months ended September 30, 2016 . Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense CoLucid Pharmaceuticals, Inc. (CoLucid) Oral therapy for the acute treatment of migraine - lasmiditan March 2017 Phase III $ 857.6 KeyBioscience AG (KeyBioscience) Multiple molecules for treatment of metabolic disorders July 2017 Phase II $ 55.0 Nektar Therapeutics (Nektar) Immunological therapy - NKTR-358 August 2017 Phase I $ 150.0 (1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 3, 2017 Inventories $ 108.6 Marketed products (1) 298.0 Property and equipment 148.2 Other assets and liabilities - net 5.2 Total identifiable net assets 560.0 Goodwill (2) 322.1 Total consideration transferred - net of cash acquired $ 882.1 (1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years . (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. We anticipate that the goodwill associated with this acquisition will be deductible for tax purposes.

Collaborations and Other Arra25

Collaborations and Other Arrangements (Tables)	9 Months Ended
	Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Marketing Rights	We and Daiichi Sankyo each have exclusive marketing rights in certain other territories. Territory Marketing Rights Selling Party U.S. Co-promotion Lilly Major European markets Co-promotion Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo Japan Exclusive Daiichi Sankyo
Diabetes Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration: Year Launched Milestones (Deferred) Capitalized (1) Product Family U.S. Europe Japan Year Amount Trajenta (2) 2011 2011 2011 Cumulative (4) - all prior to 2016 $ 446.4 Jardiance (3) 2014 2014 2015 Cumulative (4) - all prior to 2016 299.5 Basaglar 2016 2015 2015 2017 — 2016 (187.5 ) Cumulative (4) (250.0 ) (1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales. (2) Jentadueto is included in the Trajenta family of product results. (3) Glyxambi and Synjardy are included in the Jardiance family of product results. (4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
Bi Compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Trajenta $ 153.3 $ 115.4 $ 408.2 $ 330.8 Jardiance 127.2 47.5 304.3 125.8 Basaglar 145.7 19.4 278.3 46.6
Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table summarizes our revenue recognized with respect to Erbitux: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net product revenue $ 137.6 $ 155.9 $ 403.3 $ 455.8 Collaboration and other revenue 25.9 28.7 73.7 77.5 Revenue $ 163.5 $ 184.6 $ 477.0 $ 533.3
Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table summarizes our revenue recognized with respect to Effient: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenue $ 55.9 $ 127.7 $ 326.6 $ 394.3
Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated condensed statements of operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Collaboration and other revenue $ 334.2 $ 216.5 $ 869.1 $ 607.3

Asset Impairment, Restructuri26

Asset Impairment, Restructuring, and Other Special Charges (Tables)	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. Three Months Ended Nine Months Ended 2017 2016 2017 2016 Severance: Human pharmaceutical products $ 165.7 $ — $ 277.1 $ — Animal health products 5.8 8.3 62.1 37.0 Total severance 171.5 8.3 339.2 37.0 Asset impairment and other special charges: Human pharmaceutical products 25.0 — 25.0 — Animal health products 210.0 37.2 306.2 197.9 Total asset impairment and other special charges 235.0 37.2 331.2 197.9 Total asset impairment, restructuring, and other special charges $ 406.5 $ 45.5 $ 670.4 $ 234.9

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	The following effects of risk-management instruments were recognized in other–net, (income) expense: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Fair value hedges: Effect from hedged fixed-rate debt $ (4.0 ) $ (18.8 ) $ 3.6 $ 92.4 Effect from interest rate contracts 4.0 18.8 (3.6 ) (92.4 ) Cash flow hedges: Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 3.7 3.8 11.1 11.2 Net losses on foreign currency exchange contracts not designated as hedging instruments 16.3 1.4 79.2 105.6
Fair Value, Assets Measured on Recurring Basis	The following tables summarize certain fair value information at September 30, 2017 and December 31, 2016 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2017 Cash equivalents $ 2,066.7 $ 2,066.7 $ 1,611.0 $ 455.7 $ — $ 2,066.7 Short-term investments: U.S. government and agency securities $ 742.2 $ 742.7 $ 742.2 $ — $ — $ 742.2 Corporate debt securities 2,322.9 2,322.4 — 2,322.9 — 2,322.9 Asset-backed securities 149.8 149.8 — 149.8 — 149.8 Other securities 3.9 3.9 — 3.9 — 3.9 Short-term investments $ 3,218.8 Noncurrent investments: U.S. government and agency securities $ 411.7 $ 415.3 $ 411.7 $ — $ — $ 411.7 Corporate debt securities 3,913.2 3,903.8 — 3,913.2 — 3,913.2 Mortgage-backed securities 165.1 166.0 — 165.1 — 165.1 Asset-backed securities 638.8 639.2 — 638.8 — 638.8 Other securities 130.7 75.5 — — 130.7 130.7 Marketable equity securities 344.7 127.5 344.7 — — 344.7 Cost and equity method investments (2) 544.5 Noncurrent investments $ 6,148.7 December 31, 2016 Cash equivalents $ 2,986.8 $ 2,986.8 $ 2,699.4 $ 287.4 $ — $ 2,986.8 Short-term investments: U.S. government and agency securities $ 232.5 $ 232.6 $ 232.5 $ — $ — $ 232.5 Corporate debt securities 1,219.2 1,219.1 — 1,219.2 — 1,219.2 Asset-backed securities 4.3 4.3 — 4.3 — 4.3 Other securities 0.5 0.5 — 0.5 — 0.5 Short-term investments $ 1,456.5 Noncurrent investments: U.S. government and agency securities $ 318.9 $ 323.8 $ 318.9 $ — $ — $ 318.9 Corporate debt securities 3,062.2 3,074.3 — 3,062.2 — 3,062.2 Mortgage-backed securities 183.1 185.4 — 183.1 — 183.1 Asset-backed securities 502.7 503.5 — 502.7 — 502.7 Other securities 153.7 77.6 — — 153.7 153.7 Marketable equity securities 418.2 91.9 418.2 — — 418.2 Cost and equity method investments (2) 568.7 Noncurrent investments $ 5,207.5 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) Fair value disclosures are not applicable for cost method and equity method investments.
Fair Value, Liabilities Measured on Recurring Basis	Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term commercial paper borrowings September 30, 2017 $ (2,526.0 ) $ — $ (2,523.7 ) $ — $ (2,523.7 ) December 31, 2016 (1,299.3 ) — (1,299.3 ) — (1,299.3 ) Long-term debt, including current portion September 30, 2017 $ (10,938.7 ) $ — $ (11,448.4 ) $ — $ (11,448.4 ) December 31, 2016 (9,005.9 ) — (9,419.1 ) — (9,419.1 )
Fair Value, by Balance Sheet Grouping	Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2017 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 2.0 $ — $ 2.0 $ — $ 2.0 Sundry 43.0 — 43.0 — 43.0 Other current liabilities (0.4 ) — (0.4 ) — (0.4 ) Other noncurrent liabilities (1.8 ) — (1.8 ) — (1.8 ) Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities (43.4 ) — (43.4 ) — (43.4 ) Other noncurrent liabilities (20.5 ) — (20.5 ) — (20.5 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 21.0 — 21.0 — 21.0 Other current liabilities (13.9 ) — (13.9 ) — (13.9 ) Contingent consideration liabilities (1) : Other current liabilities (201.8 ) — — (201.8 ) (201.8 ) Other noncurrent liabilities (92.2 ) — — (92.2 ) (92.2 ) December 31, 2016 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 2.4 $ — $ 2.4 $ — $ 2.4 Sundry 37.0 — 37.0 — 37.0 Other noncurrent liabilities (0.5 ) — (0.5 ) — (0.5 ) Cross-currency interest rate contracts designated as net investment hedges: Sundry 31.4 — 31.4 — 31.4 Foreign exchange contracts not designated as hedging instruments: Other receivables 31.8 — 31.8 — 31.8 Other current liabilities (21.7 ) — (21.7 ) — (21.7 ) Contingent consideration liabilities (1) : Other current liabilities (215.9 ) — — (215.9 ) (215.9 ) Other noncurrent liabilities (242.6 ) — — (242.6 ) (242.6 ) (1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.
Available-for-sale Securities	The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2017 : Maturities by Period Total Less Than 1 Year 1-5 Years 6-10 Years More Than 10 Years Fair value of debt securities $ 8,343.7 $ 3,214.9 $ 4,795.2 $ 122.4 $ 211.2 A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: September 30, 2017 December 31, 2016 Unrealized gross gains $ 259.7 $ 352.6 Unrealized gross losses 27.2 34.1 Fair value of securities in an unrealized gain position 3,400.7 1,869.7 Fair value of securities in an unrealized loss position 4,013.9 3,262.3
Gain (Loss) on Investments	Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Proceeds from sales $ 951.5 $ 926.3 $ 3,003.0 $ 2,503.4 Realized gross gains on sales 9.0 12.8 82.9 18.0 Realized gross losses on sales 0.8 1.3 3.2 11.7
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net investment hedges: Foreign currency-denominated notes $ (58.7 ) $ (37.0 ) $ (332.0 ) $ (80.0 ) Cross-currency interest rate swaps (38.2 ) (4.1 ) (95.8 ) 2.2 Foreign currency exchange contracts — — — 31.9 Cash flow hedges: Forward-starting interest rate swaps — — 13.0 (3.4 )

Retirement Benefits (Tables)

Retirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2017
Defined Benefit Pension Plans
Schedule of Net Benefit Costs	Net pension and retiree health benefit (income) cost included the following components: Defined Benefit Pension Plans Three Months Ended Nine Months Ended 2017 2016 2017 2016 Components of net periodic benefit cost: Service cost $ 86.0 $ 70.2 $ 251.6 $ 212.2 Interest cost 103.6 104.2 309.2 314.4 Expected return on plan assets (196.4 ) (187.6 ) (585.7 ) (566.7 ) Amortization of prior service cost 1.4 2.9 4.3 8.6 Recognized actuarial loss 72.5 71.0 215.6 213.4 Net periodic benefit cost $ 67.1 $ 60.7 $ 195.0 $ 181.9
Retiree Health Benefit Plans
Schedule of Net Benefit Costs	Retiree Health Benefit Plans Three Months Ended Nine Months Ended 2017 2016 2017 2016 Components of net periodic benefit income: Service cost $ 11.6 $ 9.7 $ 34.8 $ 29.3 Interest cost 13.2 13.0 39.6 39.0 Expected return on plan assets (40.2 ) (37.6 ) (120.6 ) (112.7 ) Amortization of prior service benefit (22.5 ) (21.5 ) (67.5 ) (64.3 ) Recognized actuarial loss 4.6 5.2 13.8 15.5 Net periodic benefit income $ (33.3 ) $ (31.2 ) $ (99.9 ) $ (93.2 )

Other Comprehensive Income (L29

Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows: Three Months Ended Nine Months Ended Tax benefit (expense) 2017 2016 2017 2016 Foreign currency translation gains/losses $ 33.9 $ 14.4 $ 149.7 $ 16.1 Unrealized net gains/losses on securities (4.2 ) (26.1 ) 25.4 (40.5 ) Defined benefit pension and retiree health benefit plans (9.4 ) (9.5 ) (24.0 ) (57.0 ) Effective portion of cash flow hedges (1.3 ) (1.3 ) (8.4 ) (2.7 ) Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ 19.0 $ (22.5 ) $ 142.7 $ (84.1 ) The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2017 and 2016 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2017 $ (1,349.4 ) $ 153.2 $ (3,348.5 ) $ (197.6 ) $ (4,742.3 ) Other comprehensive income (loss) before reclassifications 135.8 33.9 (28.7 ) — 141.0 Net amount reclassified from accumulated other comprehensive loss 8.1 (23.9 ) 40.1 2.4 26.7 Net other comprehensive income (loss) 143.9 10.0 11.4 2.4 167.7 Balance at September 30, 2017 (2) $ (1,205.5 ) $ 163.2 $ (3,337.1 ) $ (195.2 ) $ (4,574.6 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2016 $ (1,273.0 ) $ 36.8 $ (2,919.1 ) $ (215.9 ) $ (4,371.2 ) Other comprehensive income (loss) before reclassifications 5.8 48.9 18.7 — 73.4 Net amount reclassified from accumulated other comprehensive loss — (0.4 ) 38.0 2.5 40.1 Net other comprehensive income (loss) 5.8 48.5 56.7 2.5 113.5 Balance at September 30, 2016 (2) $ (1,267.2 ) $ 85.3 $ (2,862.4 ) $ (213.4 ) $ (4,257.7 ) The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2017 and 2016 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2017 (1) $ (1,867.3 ) $ 224.0 $ (3,371.6 ) $ (210.9 ) $ (5,225.8 ) Other comprehensive income (loss) before reclassifications 653.7 9.6 (83.3 ) 8.4 588.4 Net amount reclassified from accumulated other comprehensive loss 8.1 (70.4 ) 117.8 7.3 62.8 Net other comprehensive income (loss) 661.8 (60.8 ) 34.5 15.7 651.2 Balance at September 30, 2017 (2) $ (1,205.5 ) $ 163.2 $ (3,337.1 ) $ (195.2 ) $ (4,574.6 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2016 (1) $ (1,360.2 ) $ 10.1 $ (3,012.1 ) $ (218.5 ) $ (4,580.7 ) Other comprehensive income (loss) before reclassifications 18.5 61.9 39.2 (2.2 ) 117.4 Net amount reclassified from accumulated other comprehensive loss 74.5 13.3 110.5 7.3 205.6 Net other comprehensive income (loss) 93.0 75.2 149.7 5.1 323.0 Balance at September 30, 2016 (2) $ (1,267.2 ) $ 85.3 $ (2,862.4 ) $ (213.4 ) $ (4,257.7 ) (1) Accumulated other comprehensive loss as of January 1, 2017 consists of $5,274.0 million of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to non-controlling interest. The accumulated other comprehensive loss attributable to non-controlling interest as of January 1, 2016 is immaterial. (2) Accumulated other comprehensive loss as of September 30, 2017 consists of $4,609.4 million of accumulated other comprehensive loss attributable to controlling interest and $34.8 million of accumulated other comprehensive income attributable to non-controlling interest. The accumulated other comprehensive loss attributable to non-controlling interest as of September 30, 2016 is immaterial.
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated other comprehensive loss were as follows: Details about Accumulated Other Comprehensive Loss Components Three Months Ended Nine Months Ended Affected Line Item in the Consolidated Condensed Statements of Operations 2017 2016 2017 2016 Amortization of retirement benefit items: Prior service benefits, net $ (21.1 ) $ (18.6 ) $ (63.2 ) $ (55.7 ) (1) Actuarial losses, net 77.1 76.2 229.4 228.9 (1) Total before tax 56.0 57.6 166.2 173.2 Tax benefit (15.9 ) (19.6 ) (48.4 ) (62.7 ) Income taxes Net of tax 40.1 38.0 117.8 110.5 Unrealized gains/losses on available-for-sale securities: Realized gains, net before tax (36.7 ) (12.0 ) (108.2 ) (6.8 ) Other–net, (income) expense Impairment losses — 11.4 — 27.3 Other–net, (income) expense Total before tax (36.7 ) (0.6 ) (108.2 ) 20.5 Tax (benefit) expense 12.8 0.2 37.8 (7.2 ) Income taxes Net of tax (23.9 ) (0.4 ) (70.4 ) 13.3 Other, net of tax (2) 10.5 2.5 15.4 81.8 Other–net, (income) expense Total reclassifications for the period (net of tax) $ 26.7 $ 40.1 $ 62.8 $ 205.6 (1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 9). (2) Amount for the nine months ended September 30, 2016 included primarily $74.5 million of foreign currency translation losses.

Other - Net, (Income) Expense

Other - Net, (Income) Expense (Tables)	9 Months Ended
	Sep. 30, 2017
Nonoperating Income (Expense) [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other–net, (income) expense consisted of the following: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Interest expense $ 61.9 $ 47.2 $ 162.1 $ 133.8 Interest income (45.1 ) (29.1 ) (114.6 ) (76.8 ) Venezuela charge — — — 203.9 Other income (2.9 ) (45.3 ) (44.8 ) (160.3 ) Other–net, (income) expense $ 13.9 $ (27.2 ) $ 2.7 $ 100.6

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Three Months Ended Nine Months Ended 2017 2016 2017 2016 Segment revenue—to unaffiliated customers: Human pharmaceutical products: Endocrinology: Humalog ® $ 696.2 $ 640.8 $ 2,083.0 $ 1,949.0 Trulicity ® 527.7 243.6 1,380.8 588.5 Forteo ® 441.7 391.2 1,235.8 1,077.5 Humulin ® 300.5 322.0 972.8 1,010.6 Trajenta 153.3 115.4 408.2 330.8 Other Endocrinology 441.3 262.8 1,094.4 734.5 Total Endocrinology 2,560.7 1,975.8 7,175.0 5,690.9 Oncology: Alimta 514.5 570.4 1,537.3 1,741.7 Cyramza ® 196.0 159.0 553.5 437.0 Erbitux 163.5 184.6 477.0 533.3 Other Oncology 83.6 33.3 232.7 100.3 Total Oncology 957.6 947.3 2,800.5 2,812.3 Cardiovascular: Cialis ® 564.9 588.2 1,725.7 1,795.3 Effient 55.9 127.7 326.6 394.3 Other Cardiovascular 42.1 57.6 120.2 165.4 Total Cardiovascular 662.9 773.5 2,172.5 2,355.0 Neuroscience: Cymbalta (1) 183.2 313.5 564.4 748.7 Strattera ® 137.1 198.8 519.9 611.5 Zyprexa ® 140.6 148.9 428.9 572.3 Other Neuroscience 46.8 47.3 160.5 137.4 Total Neuroscience 507.7 708.5 1,673.7 2,069.9 Immunology: Taltz ® 151.3 32.5 386.7 51.9 Other Immunology 16.3 — 22.9 — Total Immunology 167.6 32.5 409.6 51.9 Other pharmaceuticals 60.9 47.9 184.5 161.1 Total human pharmaceutical products 4,917.4 4,485.5 14,415.8 13,141.1 Animal health products 740.6 706.2 2,294.8 2,320.5 Revenue $ 5,658.0 $ 5,191.7 $ 16,710.6 $ 15,461.6 Three Months Ended Nine Months Ended 2017 2016 2017 2016 Segment profits: Human pharmaceutical products $ 1,242.5 $ 1,089.0 $ 3,765.7 $ 2,975.3 Animal health products 121.9 104.9 422.6 464.3 Total segment profits $ 1,364.4 $ 1,193.9 $ 4,188.3 $ 3,439.6 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 1,364.4 $ 1,193.9 $ 4,188.3 $ 3,439.6 Other profits (losses): Acquired in-process research and development (Note 3) (205.0 ) — (1,062.6 ) — Amortization of intangible assets (155.8 ) (177.7 ) (510.0 ) (518.8 ) Asset impairment, restructuring, and other special charges (Note 5) (406.5 ) (45.5 ) (670.4 ) (234.9 ) Inventory fair value adjustment related to BIVIVP (Note 3) (5.5 ) — (32.0 ) — Venezuela charge (Note 12) — — — (203.9 ) Consolidated income before taxes $ 591.6 $ 970.7 $ 1,913.3 $ 2,482.0 Numbers may not add due to rounding. (1) Cymbalta revenues include reductions to the reserve for expected product returns of approximately $145 million and $175 million during the three and nine months ended September 30, 2016 , respectively.

Basis of Presentation Basis of

Basis of Presentation Basis of Presentation (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net Cash Provided by (Used in) Operating Activities	$ 3,872.1	$ 2,844.5
Net Cash Provided by (Used in) Financing Activities	$ 684.9	(945)
Adjustments for New Accounting Pronouncement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net Cash Provided by (Used in) Operating Activities		110.4
Net Cash Provided by (Used in) Financing Activities		$ (110.4)

Implementation of New Financi33

Implementation of New Financial Accounting Pronouncements (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2017
Concentration Risk [Line Items]
New Accounting Pronouncement or Change in Accounting Principle Not Yet Adopted, Estimated Cumulative Effect of Change on Equity Upon Adoption		$ 2
New Accounting Pronouncement or Change in Accounting Principle Not Yet Adopted, Estimated Effect of Change on Deferred Tax Assets		$ 2
Revenue from Rights Concentration Risk [Member] | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration risk	4.00%
Product | Product Concentration Risk | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration risk	96.00%

Acquisitions (Purchased Price)

Acquisitions (Purchased Price) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jan. 03, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Acquired in-process research and development (Note 3)		$ 205	$ 0	$ 1,062.6	$ 0
Goodwill		$ 4,365.6		4,365.6			$ 3,972.7
CoLucid Pharmaceuticals
Business Acquisition [Line Items]
Acquired in-process research and development (Note 3)	$ 857.6			$ 857.6
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio
Business Acquisition [Line Items]
Inventories						$ 108.6
Marketed products						298
Property and equipment						148.2
Other assets and liabilities - net						5.2
Total identifiable net assets						560
Goodwill						322.1
Total consideration transferred - net of cash acquired						$ 882.1

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended					3 Months Ended		9 Months Ended
	Oct. 31, 2017	Aug. 31, 2017	Jul. 31, 2017	Mar. 31, 2017	Jan. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Acquired in-process research and development						$ 205	$ 0	$ 1,062.6	$ 0
Purchased in-process research and development								1,036.8	$ 0
KeyBioscience's Dual Amylin Calcitonin Receptor Agonists [Member]
Business Acquisition [Line Items]
Acquired in-process research and development			$ 55
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio
Business Acquisition [Line Items]
All cash transaction					$ 882.1
Useful life (years)					10 years
Revenue of acquired entity from the date of acquisition						$ 61.2		180.2
CoLucid Pharmaceuticals
Business Acquisition [Line Items]
Acquired in-process research and development				$ 857.6				$ 857.6
Purchased in-process research and development				831.8
Value of liabilities assumed				$ 25.8
Nektar's Phase I Immunological Therapy [Member]
Business Acquisition [Line Items]
Acquired in-process research and development		$ 150
Subsequent Event [Member] | CureVac AG
Business Acquisition [Line Items]
Purchased in-process research and development	$ 50
Subsequent Event [Member] | Scenario, Forecast | CureVac AG
Business Acquisition [Line Items]
Acquired in-process research and development	$ 50

Collaborations and Other Arra36

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	1 Months Ended				3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2014	Oct. 31, 2013	Dec. 31, 2009	Jun. 30, 2001	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and other revenue					$ 334.2		$ 216.5				$ 869.1	$ 607.3
Marketing, selling, and administrative					1,555.5		1,565.4				4,807.6	4,661.9
Revenue					5,658		5,191.7				16,710.6	15,461.6
Research and development					1,319.4		1,236.4				3,808.6	3,793.3
Acquired in-process research and development (Note 3)					205		0				1,062.6	0
Sales | Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)									38.00%
Profit and Development and Marketing Share | Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)				50.00%
Research and Development Exp | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)			30.00%
Milestone Payments, Development and Regulatory, Capitalized | Lly Compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized											0		$ (187.5)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Lly Compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized											(250)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Trajenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized											446.4
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Jardiance (BI)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized											299.5
Milestone Payments, Development and Regulatory, Expensed | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development								$ 55
Milestone Payments, Development and Regulatory, Expensed | Lanabecestat
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development					50
Milestone Payments, Sales-based | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized			$ 150
Milestone Payments, Sales-based | Tanezumab
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized		$ 1,230
Upfront Payment | Tanezumab
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Acquired in-process research and development (Note 3)										$ 200
Milestone Payments, Development and Regulatory | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized			280
Milestone Payments, Development and Regulatory | Tanezumab
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized		$ 350
Milestone Payments, Development and Regulatory | Lanabecestat
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized	$ 300
Research and development							100
Milestone Payments, Development and Regulatory, First Indication | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized			$ 100
Royalty Agreement Terms | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)			20.00%
Human pharmaceutical products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					4,917.4		4,485.5				14,415.8	13,141.1
Human pharmaceutical products | Lly Compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					145.7		19.4						$ 278.3	$ 46.6
Human pharmaceutical products | Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and other revenue					25.9		28.7				73.7	77.5
Collaboration and other revenue					137.6		155.9				403.3	455.8
Revenue					163.5		184.6				477	533.3
Human pharmaceutical products | Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					55.9		127.7				326.6	394.3
Human pharmaceutical products | Trajenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and other revenue					153.3		115.4				408.2	330.8
Human pharmaceutical products | Jardiance (BI)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and other revenue					127.2		$ 47.5				$ 304.3	$ 125.8
Europe | Milestone Payments, Development and Regulatory, Capitalized | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized						$ 65
JAPAN | Milestone Payments, Development and Regulatory, Capitalized | Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized					$ 15

Asset Impairment, Restructuri37

Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Severance:	$ 171.5	$ 8.3	$ 339.2	$ 37
Asset impairment and other special charges:	235	37.2	331.2	197.9
Total asset impairment, restructuring, and other special charges	406.5	45.5	670.4	234.9
Expected cost of restructuring	800		800
Human pharmaceutical products
Restructuring Cost and Reserve [Line Items]
Severance:	165.7	0	277.1	0
Asset impairment and other special charges:	25	0	25	0
Animal health products
Restructuring Cost and Reserve [Line Items]
Severance:	5.8	8.3	62.1	37
Asset impairment and other special charges:	$ 210	$ 37.2	$ 306.2	197.9
Ireland | Animal health products
Restructuring Cost and Reserve [Line Items]
Asset impairment and other special charges:				$ 87.2

Financial Instruments (Effect o

Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Designated as Hedging Instrument | Effect from hedged fixed-rate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effect from hedged fixed-rate debt	$ (4)	$ (18.8)	$ 3.6	$ 92.4
Designated as Hedging Instrument | Effect from interest rate contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effect from interest rate contracts	4	18.8	(3.6)	(92.4)
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	3.7	3.8	11.1	11.2
Not Designated as Hedging Instrument | Foreign currency exchange contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net losses on foreign currency exchange contracts not designated as hedging instruments	16.3	1.4	79.2	105.6
Net investment hedges:
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	(58.7)	(37)	(332)	(80)
Net investment hedges: | Cross-currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	(38.2)	(4.1)	(95.8)	2.2
Net investment hedges: | Foreign currency exchange contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	0	0	0	31.9
Cash flow hedges: | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	$ 0	$ 0	$ 13	$ (3.4)

Financial Instruments (Fair Val

Financial Instruments (Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 2,066.7	$ 2,986.8
Short-term investments:	3,218.8	1,456.5
Noncurrent investments:	6,148.7	5,207.5
Short-term commercial paper borrowings	(2,526)	(1,299.3)
Long-term debt, including current portion	(10,938.7)	(9,005.9)
Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,066.7	2,986.8
Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,066.7	2,986.8
Short-term commercial paper borrowings	(2,523.7)	(1,299.3)
Long-term debt, including current portion	(11,448.4)	(9,419.1)
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,611	2,699.4
Short-term commercial paper borrowings	0	0
Long-term debt, including current portion	0	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	455.7	287.4
Short-term commercial paper borrowings	(2,523.7)	(1,299.3)
Long-term debt, including current portion	(11,448.4)	(9,419.1)
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Short-term commercial paper borrowings	0	0
Long-term debt, including current portion	0	0
U.S. government and agency securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	742.2	232.5
Noncurrent investments, debt securities	411.7	318.9
U.S. government and agency securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	742.7	232.6
Noncurrent investments, debt securities	415.3	323.8
U.S. government and agency securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	742.2	232.5
Noncurrent investments, debt securities	411.7	318.9
U.S. government and agency securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	742.2	232.5
Noncurrent investments, debt securities	411.7	318.9
U.S. government and agency securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
U.S. government and agency securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Corporate debt securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	2,322.9	1,219.2
Noncurrent investments, debt securities	3,913.2	3,062.2
Corporate debt securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	2,322.4	1,219.1
Noncurrent investments, debt securities	3,903.8	3,074.3
Corporate debt securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	2,322.9	1,219.2
Noncurrent investments, debt securities	3,913.2	3,062.2
Corporate debt securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Corporate debt securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	2,322.9	1,219.2
Noncurrent investments, debt securities	3,913.2	3,062.2
Corporate debt securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Mortgage-backed securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	165.1	183.1
Mortgage-backed securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	166	185.4
Mortgage-backed securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	165.1	183.1
Mortgage-backed securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	0	0
Mortgage-backed securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	165.1	183.1
Mortgage-backed securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent investments, debt securities	0	0
Asset-backed securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	149.8	4.3
Noncurrent investments, debt securities	638.8	502.7
Asset-backed securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	149.8	4.3
Noncurrent investments, debt securities	639.2	503.5
Asset-backed securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	149.8	4.3
Noncurrent investments, debt securities	638.8	502.7
Asset-backed securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Asset-backed securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	149.8	4.3
Noncurrent investments, debt securities	638.8	502.7
Asset-backed securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Other securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	3.9	0.5
Noncurrent investments, debt securities	130.7	153.7
Other securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	3.9	0.5
Noncurrent investments, debt securities	75.5	77.6
Other securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	3.9	0.5
Noncurrent investments, debt securities	130.7	153.7
Other securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	0	0
Other securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	3.9	0.5
Noncurrent investments, debt securities	0	0
Other securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments, debt securities	0	0
Noncurrent investments, debt securities	130.7	153.7
Marketable equity securities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	344.7	418.2
Marketable equity securities | Cost
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	127.5	91.9
Marketable equity securities | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	344.7	418.2
Marketable equity securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	344.7	418.2
Marketable equity securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	0	0
Marketable equity securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	0	0
Cost and equity method investments | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost and equity method investments	$ 544.5	$ 568.7

Financial Instruments (Risk Man

Financial Instruments (Risk Management Instruments) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	$ (201.8)	$ (215.9)
Other noncurrent liabilities	(92.2)	(242.6)
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(201.8)	(215.9)
Other noncurrent liabilities	(92.2)	(242.6)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	2	2.4
Sundry	43	37
Other current liabilities	(0.4)
Other noncurrent liabilities	(1.8)	(0.5)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Sundry	0	0
Other current liabilities	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	2	2.4
Sundry	43	37
Other current liabilities	(0.4)
Other noncurrent liabilities	(1.8)	(0.5)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Sundry	0	0
Other current liabilities	0
Other noncurrent liabilities	0	0
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sundry		31.4
Other current liabilities	(43.4)
Other noncurrent liabilities	(20.5)
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sundry		0
Other current liabilities	0
Other noncurrent liabilities	0
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sundry		31.4
Other current liabilities	(43.4)
Other noncurrent liabilities	(20.5)
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sundry		0
Other current liabilities	0
Other noncurrent liabilities	0
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21	31.8
Other current liabilities	(13.9)	(21.7)
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Other current liabilities	0	0
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21	31.8
Other current liabilities	(13.9)	(21.7)
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0	0
Other current liabilities	0	0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(201.8)	(215.9)
Other noncurrent liabilities	(92.2)	(242.6)
Carrying Amount | Effect from interest rate contracts | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	2	2.4
Sundry	43	37
Other current liabilities	(0.4)
Other noncurrent liabilities	(1.8)	(0.5)
Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sundry		31.4
Other current liabilities	(43.4)
Other noncurrent liabilities	(20.5)
Carrying Amount | Foreign currency exchange contracts | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21	31.8
Other current liabilities	$ (13.9)	$ (21.7)

Financial Instruments (Contract

Financial Instruments (Contractual Maturities) (Details) $ in Millions	Sep. 30, 2017USD ($)
Fair Value Disclosures [Abstract]
Total	$ 8,343.7
Less Than 1 Year	3,214.9
1-5 Years	4,795.2
6-10 Years	122.4
More Than 10 Years	$ 211.2

Financial Instruments (Unrealiz

Financial Instruments (Unrealized gain and losses) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Unrealized gross gains	$ 259.7	$ 352.6
Unrealized gross losses	27.2	34.1
Fair value of securities in an unrealized gain position	3,400.7	1,869.7
Fair value of securities in an unrealized loss position	$ 4,013.9	$ 3,262.3

Financial Instruments (Realized

Financial Instruments (Realized gain and losses) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Proceeds from sales	$ 951.5	$ 926.3	$ 3,003	$ 2,503.4
Realized gross gains on sales	9	12.8	82.9	18
Realized gross losses on sales	$ 0.8	$ 1.3	$ 3.2	$ 11.7

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

May 31, 2017USD ($)

May 31, 2016USD ($)

Sep. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2017EUR (€)

Sep. 30, 2017GBP (£)

Sep. 30, 2017USD ($)

Sep. 30, 2017JPY (¥)

Dec. 31, 2016USD ($)

May 31, 2016CHF (SFr)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Maximum remaining maturity of foreign currency derivatives

30 days

Description of derivative activity volume (percentage)

30.00%

30.00%

30.00%

30.00%

Proceeds from issuance of debt

$ 2,230

$ 1,210

Interest rate cash flow hedge gain (loss) to be reclassified during next 12 months

$ 14.7

Cash payment

$ 151.3

OTTI recognized

$ 0

$ 11.4

$ 0

$ 53

Available-for-sale, percentage of nonperforming assets (percentage)

95.00%

Amount of receivable derecognized

678.9

$ 661.6

Buy Us Dollar Sell Euro

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative liability, notional amount

502.9

Derivative asset, notional amount | €

€ 422.1

Buy Euro Sell Us Dollar

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative liability, notional amount | €

735.7

Derivative asset, notional amount

878.1

Buy US dollar Sell Japanese Yen

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative liability, notional amount

428.4

Derivative asset, notional amount | ¥

¥ 47,900

Buy British Pound Sell Euro

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative liability, notional amount | £

£ 295.9

Derivative asset, notional amount | €

€ 334.8

Buy US dollar Sell British pound

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative liability, notional amount

287.3

Derivative asset, notional amount | £

£ 212.2

Foreign Currency Denominated Debt

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Long-term debt, including current portion

$ 3,670

$ 3,340

Notes Due in May 2022

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount

$ 750

Stated interest rate (percentage)

2.35%

Notes Due in May 2027

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount

$ 750

Stated interest rate (percentage)

3.10%

Notes Due in May 2047

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount

$ 750

Stated interest rate (percentage)

3.95%

Notes Due in May 2018

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount | SFr

SFr 200

Stated interest rate (percentage)

0.00%

Notes Due in May 2024

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount | SFr

SFr 600

Stated interest rate (percentage)

0.15%

Notes Due in May 2028

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, face amount | SFr

SFr 400

Stated interest rate (percentage)

0.45%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Oct. 31, 2013
Stockholders' Equity Note [Abstract]
Shares repurchased		$ 259.9	$ 300.1
Stock repurchase program, authorized amount				$ 5,000
Purchases of common stock	$ 60	199.9	$ 300.1
Stock repurchase program, remaining authorized repurchase amount		$ 2,150

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]
Effective income tax rate (percentage)		6.10%	19.90%		24.10%	20.80%
Acquired in-process research and development (Note 3)		$ 205	$ 0		$ 1,062.6	$ 0
Tax year under examination								2,015	2,014	2,013	2,012	2,011	2,010
Unrecognized tax benefits, decrease resulting from settlements				$ 140
Income taxes paid							$ 150
CoLucid Pharmaceuticals
Operating Loss Carryforwards [Line Items]
Acquired in-process research and development (Note 3)	$ 857.6				$ 857.6

Retirement Benefits (Details)

Retirement Benefits (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
Pension contributions	$ 30
Estimated future employer contributions in current FY	$ 10

Retirement Benefits (Components

Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Defined Benefit Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 86	$ 70.2	$ 251.6	$ 212.2
Interest cost	103.6	104.2	309.2	314.4
Expected return on plan assets	(196.4)	(187.6)	(585.7)	(566.7)
Amortization of prior service cost	1.4	2.9	4.3	8.6
Recognized actuarial loss	72.5	71	215.6	213.4
Net periodic benefit cost	67.1	60.7	195	181.9
Retiree Health Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	11.6	9.7	34.8	29.3
Interest cost	13.2	13	39.6	39
Expected return on plan assets	(40.2)	(37.6)	(120.6)	(112.7)
Amortization of prior service cost	(22.5)	(21.5)	(67.5)	(64.3)
Recognized actuarial loss	4.6	5.2	13.8	15.5
Net periodic benefit cost	$ (33.3)	$ (31.2)	$ (99.9)	$ (93.2)

Contingencies (Details)

Contingencies (Details) $ in Millions, BRL in Billions	1 Months Ended		9 Months Ended
	Aug. 31, 2015plaintiff	Apr. 30, 2015USD ($)	Sep. 30, 2017BRLlawsuitclass_actionindividualplaintiffapplicationcase	Sep. 30, 2017USD ($)lawsuitclass_actionindividualplaintiffapplicationcase	Oct. 31, 2010application
UNITED STATES | Alimta
Number of new application | application			10	10	2
Product Liability Litigation | Cymbalta (1)
Number of lawsuits | lawsuit			140	140
Number of plaintiffs | plaintiff	5		1,470	1,470
Product Liability Litigation | Actos
Number of cases | case			6,700	6,700
Product Liability Litigation | Canada | Actos
Number of cases			3	3
Product Liability Litigation | Ontario | Actos
Number of cases			1	1
Product Liability Litigation | Quebec | Actos
Number of cases			1	1
Product Liability Litigation | Alberta | Actos
Number of cases			1	1
Product Liability Litigation | California | Cymbalta (1)
Number of lawsuits | individual			40	40
Employee Litigation | Brazil
Number of lawsuits | lawsuit			40	40
Damages awarded, value			BRL 1	$ 315
Number of Individuals | individual			305	305
Product Liability Litigation | Takeda Portion | Actos
Litigation settlement, amount | $		$ 2,400

Other Comprehensive Income (L50

Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				$ 14,080.5		$ 14,960.6	$ 14,080.5
Other comprehensive income (loss) before reclassifications		$ 141	$ 73.4	588.4	$ 117.4
Net amount reclassified from accumulated other comprehensive loss		26.7	40.1	62.8	205.6
Net other comprehensive income (loss)	[1]	167.7	113.5	651.2	323
Ending balance				14,080.5
Accumulated other comprehensive loss						4,609.4	5,274
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(4,742.3)	(4,371.2)	(5,225.8)	(4,580.7)	(4,574.6)	(5,225.8)	$ (4,257.7)
Ending balance		(4,742.3)	(4,371.2)	(5,225.8)	(4,580.7)
Foreign Currency Translation Gains (Losses)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(1,349.4)	(1,273)	(1,867.3)	(1,360.2)	(1,205.5)	(1,867.3)	(1,267.2)
Other comprehensive income (loss) before reclassifications		135.8	5.8	653.7	18.5
Net amount reclassified from accumulated other comprehensive loss		8.1	0	8.1	74.5
Net other comprehensive income (loss)		143.9	5.8	661.8	93
Ending balance		(1,349.4)	(1,273)	(1,867.3)	(1,360.2)
Unrealized gains/losses on available-for-sale securities:
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		153.2	36.8	224	10.1	163.2	224	85.3
Other comprehensive income (loss) before reclassifications		33.9	48.9	9.6	61.9
Net amount reclassified from accumulated other comprehensive loss		(23.9)	(0.4)	(70.4)	13.3
Net other comprehensive income (loss)		10	48.5	(60.8)	75.2
Ending balance		153.2	36.8	224	10.1
Defined Benefit Pension and Retiree Health Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(3,348.5)	(2,919.1)	(3,371.6)	(3,012.1)	(3,337.1)	(3,371.6)	(2,862.4)
Other comprehensive income (loss) before reclassifications		(28.7)	18.7	(83.3)	39.2
Net amount reclassified from accumulated other comprehensive loss		40.1	38	117.8	110.5
Net other comprehensive income (loss)		11.4	56.7	34.5	149.7
Ending balance		(3,348.5)	(2,919.1)	(3,371.6)	(3,012.1)
Effective Portion of Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(197.6)	(215.9)	(210.9)	(218.5)	(195.2)	(210.9)	$ (213.4)
Other comprehensive income (loss) before reclassifications		0	0	8.4	(2.2)
Net amount reclassified from accumulated other comprehensive loss		2.4	2.5	7.3	7.3
Net other comprehensive income (loss)		2.4	2.5	15.7	5.1
Ending balance		$ (197.6)	$ (215.9)	$ (210.9)	$ (218.5)
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Accumulated other comprehensive loss						4,609.4	5,274
AOCI Attributable to Noncontrolling Interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Accumulated other comprehensive loss						$ (34.8)	$ (48.2)
[1]	Other comprehensive income (loss) for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million of other comprehensive income attributable to controlling interest, respectively, and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to non-controlling interest, respectively. Other comprehensive income (loss) for the three and nine months ended September 30, 2016 attributable to non-controlling interest is immaterial.

Other Comprehensive Income (L51

Other Comprehensive Income (Loss) (Tax effect) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Equity [Abstract]
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	$ (33.9)	$ (14.4)	$ (149.7)	$ (16.1)
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	4.2	26.1	(25.4)	40.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax	(9.4)	(9.5)	(24)	(57)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	1.3	1.3	8.4	2.7
Other Comprehensive Income (Loss), Tax	$ (19)	$ 22.5	$ (142.7)	$ 84.1

Other Comprehensive Income (L52

Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other–net, (income) expense	$ 2.9	$ 45.3	$ 44.8	$ 160.3
Total before tax	591.6	970.7	1,913.3	2,482
Tax (benefit) expense	36	192.7	460.5	516.2
Other, net of tax	2.9	45.3	44.8	160.3
Total reclassifications for the period (net of tax)	(26.7)	(40.1)	(62.8)	(205.6)
Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of retirement benefit items:	(21.1)	(18.6)	(63.2)	(55.7)
Actuarial losses, net | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of retirement benefit items:	77.1	76.2	229.4	228.9
Amortization of retirement benefit items: | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	(56)	(57.6)	(166.2)	(173.2)
Tax (benefit) expense	(15.9)	(19.6)	(48.4)	(62.7)
Net of tax	(40.1)	(38)	(117.8)	(110.5)
Unrealized gains/losses on available-for-sale securities:
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)	23.9	0.4	70.4	(13.3)
Unrealized gains/losses on available-for-sale securities: | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other–net, (income) expense	(36.7)	(12)	(108.2)	(6.8)
Total before tax	(36.7)	(0.6)	(108.2)	20.5
Tax (benefit) expense	(12.8)	(0.2)	(37.8)	7.2
Net of tax	(23.9)	(0.4)	(70.4)	13.3
Other, net of tax	(36.7)	(12)	(108.2)	(6.8)
Impairment losses | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other–net, (income) expense	0	11.4	0	27.3
Other, net of tax	0	11.4	0	27.3
Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other–net, (income) expense	10.5	2.5	15.4	81.8
Other, net of tax	10.5	2.5	15.4	81.8
Foreign currency translation losses
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)	$ (8.1)	$ 0	$ (8.1)	(74.5)
Foreign currency translation losses | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other–net, (income) expense				(74.5)
Other, net of tax				$ (74.5)

Other - Net, (Income) Expense53

Other - Net, (Income) Expense (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016
Nonoperating Income (Expense) [Abstract]
Interest expense	$ 61.9	$ 47.2		$ 162.1	$ 133.8
Interest income	(45.1)	(29.1)		(114.6)	(76.8)
Venezuela charge	0	0	$ 203.9	0	203.9
Other income	(2.9)	(45.3)		(44.8)	(160.3)
Other–net, (income) expense	$ 13.9	$ (27.2)		$ 2.7	$ 100.6

Segment Information (Revenue by

Segment Information (Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 5,658	$ 5,191.7	$ 16,710.6	$ 15,461.6
Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	4,917.4	4,485.5	14,415.8	13,141.1
Animal health products
Segment Reporting Information [Line Items]
Revenue	740.6	706.2	2,294.8	2,320.5
Endocrinology: | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	2,560.7	1,975.8	7,175	5,690.9
Humalog® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	696.2	640.8	2,083	1,949
Trulicity® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	527.7	243.6	1,380.8	588.5
Forteo® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	441.7	391.2	1,235.8	1,077.5
Humulin® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	300.5	322	972.8	1,010.6
Other Endocrinology | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	441.3	262.8	1,094.4	734.5
Oncology: | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	957.6	947.3	2,800.5	2,812.3
Alimta | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	514.5	570.4	1,537.3	1,741.7
Cyramza® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	196	159	553.5	437
Erbitux | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	163.5	184.6	477	533.3
Other Oncology | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	83.6	33.3	232.7	100.3
Cardiovascular: | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	662.9	773.5	2,172.5	2,355
Cialis® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	564.9	588.2	1,725.7	1,795.3
Effient | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	55.9	127.7	326.6	394.3
Other Cardiovascular | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	42.1	57.6	120.2	165.4
Neuroscience: | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	507.7	708.5	1,673.7	2,069.9
Strattera® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	137.1	198.8	519.9	611.5
Cymbalta (1) | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	183.2	313.5	564.4	748.7
Zyprexa® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	140.6	148.9	428.9	572.3
Other Neuroscience | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	46.8	47.3	160.5	137.4
Other pharmaceuticals | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	$ 60.9	$ 47.9	$ 184.5	$ 161.1

Segment Information (Segment pr

Segment Information (Segment profit) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Other Revenue, Net	$ 334.2	$ 216.5		$ 869.1	$ 607.3
Revenue	5,658	5,191.7		16,710.6	15,461.6
Segment profits	591.6	970.7		1,913.3	2,482
Acquired in-process research and development	(205)	0		(1,062.6)	0
Asset impairment, restructuring, and other special charges (Note 5)	(406.5)	(45.5)		(670.4)	(234.9)
Cost of sales	(1,566.1)	(1,400.9)		(4,445.4)	(4,188.9)
Inventory fair value adjustment related to BIVIVP (Note 3)	0	0	$ (203.9)	0	(203.9)
Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	4,917.4	4,485.5		14,415.8	13,141.1
Segment profits	1,242.5	1,089		3,765.7	2,975.3
Animal health products
Segment Reporting Information [Line Items]
Segment profits	121.9	104.9		422.6	464.3
Operating Segments
Segment Reporting Information [Line Items]
Segment profits	1,364.4	1,193.9		4,188.3	3,439.6
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Acquired in-process research and development	(205)	0		(1,062.6)	0
Amortization of intangible assets	(155.8)	(177.7)		(510)	(518.8)
Asset impairment, restructuring, and other special charges (Note 5)	(406.5)	(45.5)		(670.4)	(234.9)
Inventory fair value adjustment related to BIVIVP (Note 3)	0	0		0	(203.9)
Fair Value Adjustment to Inventory | Corporate, Non-Segment
Segment Reporting Information [Line Items]
Cost of sales	(5.5)	0		(32)	0
Taltz [Member] | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	151.3	32.5		386.7	51.9
Other Immunology [Member] | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	16.3	0		22.9	0
Strattera® | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	137.1	198.8		519.9	611.5
Immunology [Member] | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	$ 167.6	$ 32.5		$ 409.6	$ 51.9

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)segment	Sep. 30, 2016USD ($)
Segment Reporting Information [Line Items]
Revenue	$ 5,658	$ 5,191.7	$ 16,710.6	$ 15,461.6
Number of Operating Segments | segment			2
Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	4,917.4	4,485.5	$ 14,415.8	13,141.1
Cymbalta | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue	$ 183.2	313.5	$ 564.4	748.7
Cymbalta | Adjustment to Return Reserve | Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue		$ 145		$ 175